References in periodicals archive ?
This would lead to activation of RSK in Carney complex patients and contribute to tumour growth.
Currently there are no drugs to specifically treat Carney complex.
The concept of PEM as a distinct clinicopathologic entity was further validated by a recent study (12) showing that PEM frequently shows loss of expression of cyclic AMP-dependent protein kinase 1 regulatory subunit 1a (R1[alpha]), a product of a gene mutated in families with Carney complex.
They also discuss in great detail the relationship of pigmented epithelioid melanocytoma and epithelioid blue nevus of Carney complex.